Analysts take a look at Walgreens Boots Alliance, Inc. (NASDAQ:WBA) having this to say.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Logo

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Ratings Coverage

Among 5 analysts covering Walgreens Boots Alliance (NASDAQ:WBA), 0 have Buy rating, 1 Sell and 4 Hold. Therefore 0 are positive. Walgreens Boots Alliance has $7400 highest and $49 lowest target. $60.17’s average target is 7.47% above currents $55.99 stock price. Walgreens Boots Alliance had 11 analyst reports since March 18, 2019 according to SRatingsIntel. The stock has “Sell” rating by UBS on Wednesday, April 3. The firm has “Neutral” rating given on Wednesday, April 3 by Citigroup. The rating was downgraded by Loop Capital on Wednesday, April 3 to “Hold”. Morgan Stanley maintained it with “Equal-Weight” rating and $5800 target in Friday, August 23 report. Barclays Capital maintained Walgreens Boots Alliance, Inc. (NASDAQ:WBA) rating on Wednesday, April 3. Barclays Capital has “Equal-Weight” rating and $60 target. Morgan Stanley maintained it with “Equal-Weight” rating and $61 target in Wednesday, April 3 report. Below is a list of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) latest ratings and price target changes.

23/08/2019 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $61.0000 New Target: $58.0000 Maintain
28/06/2019 Broker: Inc. – Common Stock Rating: Jp Morgan New Target: $74.0000 73.0000
03/06/2019 Broker: Inc. – Common Stock Rating: Bank Of America New Target: $53.0000 51.0000
30/05/2019 Broker: BidaskScore Rating: Sell Upgrade
13/04/2019 Broker: BidaskScore Rating: Sell Downgrade
03/04/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $67 New Target: $61 Maintain
03/04/2019 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $76 New Target: $60 Maintain
03/04/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $78 New Target: $60 Maintain
03/04/2019 Broker: UBS Old Rating: Sell New Rating: Sell Old Target: $60 New Target: $49 Maintain
03/04/2019 Broker: Loop Capital Old Rating: Buy New Rating: Hold Old Target: $77 New Target: $60 Downgrade

The stock increased 0.77% or $0.43 during the last trading session, reaching $55.99. About 3.26 million shares traded. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has declined 21.21% since September 13, 2018 and is downtrending. It has underperformed by 21.21% the S&P500.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company has market cap of $50.57 billion. It operates through three divisions: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. It has a 10.96 P/E ratio. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

More notable recent Walgreens Boots Alliance, Inc. (NASDAQ:WBA) news were published by: Nasdaq.com which released: “Market Close Report: NASDAQ Composite index closes at 7,962.88 down -10.51 points – Nasdaq” on August 30, 2019, also Nasdaq.com with their article: “Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know – Nasdaq” published on June 12, 2019, Nasdaq.com published: “Walgreens Boots Alliance a Top Ranked SAFE Dividend Stock With 2.9% Yield (WBA) – Nasdaq” on March 07, 2019. More interesting news about Walgreens Boots Alliance, Inc. (NASDAQ:WBA) were released by: Businesswire.com and their article: “Walgreens Boots Alliance Appoints Global Chief Information Officer – Business Wire” published on September 06, 2019 as well as Seekingalpha.com‘s news article titled: “Deutsche Bank likes CVS Health, sees 42% upside – Seeking Alpha” with publication date: September 12, 2019.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.